Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Eva Choong, François Veuve, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F Günthard, Jessy J Duran Ramirez, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Marcel Stöckle, Caroline Di Benedetto, Enos Bernasconi, Patrick Schmid, Catia Marzolini, François R Girardin, Thierry Buclin, Laurent A Decosterd, Monia Guidi
Long-acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings. The present population pharmacokinetic analysis aims to build real-world reference percentile curves of cabotegravir concentrations, accounting for patient-related factors that may affect cabotegravir exposure. The second objective is to simulate whether dosing interval adjustments of cabotegravir could be considered in specific subpopulations...
March 22, 2024: Clinical Pharmacology and Therapeutics